Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

The present invention is directed to a method for preparing a final phenolic product from biomass comprising the steps of providing a furanic compound obtainable from biomass; reacting the furanic compound with a dienophile to obtain a phenolic compound; reacting the phenolic compound further to obtain the final phenolic product.

The present invention is directed to a method for preparing a final phenolic product from biomass comprising the steps of providing a furanic compound obtainable from biomass; reacting the furanic compound with a dienophile to obtain a phenolic compound; reacting the phenolic compound further to obtain the final phenolic product.

Disclosed herein is an overbased alkaline earth metal hydrocarbyl-substituted salicylate detergent comprising both carbonate and borate moieties and exhibiting the following characteristics: a basicity index of at least 3.8; a ratio of soap content to mass % boron is greater than 55 mmol/kg; a soap content of at least 330 mmol/kg; a TBN, measured according to ASTM D2896, of at least 220 mg KOH/g; and a mass ratio of borate to carbonate from 0.75 to 6.0, wherein the alkaline earth metal comprises calcium and/or magnesium, and the hydrocarbyl substitution comprises 9 to 30 carbon atoms. Methods of making the boron-containing salicylate detergent, specifically to be package-stable, are also disclosed, as well as package-stable lubricant additive package concentrates and lubricating oil compositions containing same.

Disclosed herein is an overbased alkaline earth metal hydrocarbyl-substituted salicylate detergent comprising both carbonate and borate moieties and exhibiting the following characteristics: a basicity index of at least 3.8; a ratio of soap content to mass % boron is greater than 55 mmol/kg; a soap content of at least 330 mmol/kg; a TBN, measured according to ASTM D2896, of at least 220 mg KOH/g; and a mass ratio of borate to carbonate from 0.75 to 6.0, wherein the alkaline earth metal comprises calcium and/or magnesium, and the hydrocarbyl substitution comprises 9 to 30 carbon atoms. Methods of making the boron-containing salicylate detergent, specifically to be package-stable, are also disclosed, as well as package-stable lubricant additive package concentrates and lubricating oil compositions containing same.

The invention relates to new 1:1 olaparib:hydroxybenzoic acid cocrystals. The invention also relates to new 2:1 olaparib:hydroxybenzoic acid cocrystals which may contain no water (anhydrous) or may optionally be hydrated. The invention also relates to pharmaceutical compositions containing an olaparib hydroxybenzoic acid cocrystal of the invention and a pharmaceutically acceptable carrier. The olaparib hydroxybenzoic acid cocrystals of the invention may be useful for the treatment of diseases that benefit from inhibition of poly (ADP-ribose) polymerase (PARP).

The invention relates to new 1:1 olaparib:hydroxybenzoic acid cocrystals. The invention also relates to new 2:1 olaparib:hydroxybenzoic acid cocrystals which may contain no water (anhydrous) or may optionally be hydrated. The invention also relates to pharmaceutical compositions containing an olaparib hydroxybenzoic acid cocrystal of the invention and a pharmaceutically acceptable carrier. The olaparib hydroxybenzoic acid cocrystals of the invention may be useful for the treatment of diseases that benefit from inhibition of poly (ADP-ribose) polymerase (PARP).

The invention relates to a novel process for preparing spiro derivatives, in particular 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one, and to novel intermediates for use in said process along with processes for preparing said intermediates.

The invention relates to a novel process for preparing spiro derivatives, in particular 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one, and to novel intermediates for use in said process along with processes for preparing said intermediates.